Author:
Mortensen Eric M,Restrepo Marcos I,Anzueto Antonio,Pugh Jacqueline
Abstract
Abstract
Background
Recent studies suggest that HMG-CoA reductase inhibitors ("statins") may have beneficial effects for patients at risk for some types of infections. We examined the effect of prior outpatient use of statins on mortality for patients hospitalized with community-acquired pneumonia.
Methods
A retrospective cohort study conducted at two tertiary teaching hospitals. Eligible subjects were admitted with a diagnosis of, had a chest x-ray consistent with, and had a discharge ICD-9 diagnosis of pneumonia. Subjects were excluded if they were "comfort measures only" or transferred from another acute care hospital. Subjects were considered to be on a medication if they were taking it at the time of presentation.
Results
Data was abstracted on 787 subjects at the two hospitals. Mortality was 9.2% at 30-days and 13.6% at 90-days. At presentation 52% of subjects were low risk, 34% were moderate risk, and 14% were high risk based on the pneumonia severity index. In the multivariable regression analysis, after adjusting for potential confounders including a propensity score, the use of statins at presentation (odds ratio 0.36, 95% confidence interval 0.14–0.92) was associated with decreased 30-day mortality.
Discussion
Prior outpatient statin use was associated with decreased mortality in patients hospitalized with community-acquired pneumonia despite their use being associated with comorbid illnesses likely to contribute to increased mortality. Confirmatory studies are needed, as well as research to determine the mechanism(s) of this protective effect.
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Hoyert DL, Arias E, Smith BL: Deaths: Final Data for 1999.
Natl Vital Statistics Report 2001,49(8):1–113.
2. Gilbert K, Fine MJ: Assessing prognosis and predicting patient outcomes in community-acquired pneumonia.
Seminars in Respiratory Infections 1994,9(3):140–152.
3. Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S: Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Circulation 2001,103(15):1933–1935.
4. Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, Szczeklik A: Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia.
International Journal of Cardiology 2001,77(2–3):247–253.
5. de Bont N, Netea MG, Rovers C, Smilde T, Demacker PN, van der Meer JW, Stalenhoef AF: LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Atherosclerosis 1998,139(1):147–152.
Cited by
158 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献